Form 4: Catalyst Pharmaceuticals Executive Brian Elsbernd Acquires Stock Options and Restricted Stock Units

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, has acquired stock options and restricted stock units, increasing his beneficial ownership in the company.

Summary

• Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, acquired 126,704 stock options with an exercise price of $21.12 on November 21, 2024.
• These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
• Additionally, Elsbernd received 15,483 restricted stock units (RSUs) on the same date, which will convert to common stock upon vesting.
• Following these transactions, Elsbernd's direct holdings increased to 1,139,527 options and 1,155,010 RSUs.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with shareholder value. There are no negative implications.

Positives

• The acquisition of stock options and RSUs by a key executive like Brian Elsbernd can be seen as a positive sign of confidence in the company's future performance.
• The vesting schedule of the options and RSUs may incentivize long-term commitment and performance from the executive.

Industry Context

This is a standard SEC Form 4 filing, which is common for executives receiving stock-based compensation. It reflects typical practices in the pharmaceutical industry for aligning executive interests with shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, used by companies like Biogen, Amgen, and Gilead Sciences.
• The vesting schedule of the options and RSUs is also typical, often spread over several years to encourage long-term performance.
• The size of the grant is within the range of what is seen for executives at similar-sized pharmaceutical companies.

Stakeholder Impact

• The stock option and RSU grants may positively impact shareholder value if the executive's performance leads to company growth.
• The vesting schedule may incentivize the executive to focus on long-term company success.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, restricted stock units, insider trading, executive compensation, Brian Elsbernd, CPRX, beneficial ownership